Abstract
As paclitaxel may induce positive spontaneous visual symptoms or persistent visual loss, we carried out this electrophysiological study in an attempt to clarify the underlying pathophysiological mechanisms of visual pathway involvement. The study involved 30 breast cancer patients: 14 were treated with paclitaxel alone (group A) and 16 with paclitaxel and adriamycin (group B). Pattern visual evoked potentials (VEPs), and transient, 30 Hz flicker (FLK) and oscillatory potential (OP) white flash electroretinograms (ERGs), were recorded before treatment, after the third and sixth therapeutic cycle, and at the end of the programmed regimen. Pretreatment: Abnormal VEP and OP and FLK changes occurred more than 75% of patients; transient ERGs were normal in more than 90%. Serial recordings: VEPs remained unchanged in both goups. In group A, ERG b-wave latency significantly increased (ANOVA P
| Original language | English |
|---|---|
| Pages (from-to) | 79-87 |
| Number of pages | 9 |
| Journal | Journal of Neuro-Oncology |
| Volume | 77 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Mar 2006 |
Fingerprint
Keywords
- Chemotherapy
- Electroretinogram
- Ocular toxicity
- Paclitaxel
- Tamoxifen
- Visual evoked potentials
ASJC Scopus subject areas
- Clinical Neurology
- Cancer Research
- Oncology
- Neuroscience(all)
Cite this
Electrophysiological evaluation of visual pathways in paclitaxel-treated patients. / Scaioli, V.; Caraceni, A.; Martini, C.; Curzi, S.; Capri, G.; Luca, G.
In: Journal of Neuro-Oncology, Vol. 77, No. 1, 03.2006, p. 79-87.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Electrophysiological evaluation of visual pathways in paclitaxel-treated patients
AU - Scaioli, V.
AU - Caraceni, A.
AU - Martini, C.
AU - Curzi, S.
AU - Capri, G.
AU - Luca, G.
PY - 2006/3
Y1 - 2006/3
N2 - As paclitaxel may induce positive spontaneous visual symptoms or persistent visual loss, we carried out this electrophysiological study in an attempt to clarify the underlying pathophysiological mechanisms of visual pathway involvement. The study involved 30 breast cancer patients: 14 were treated with paclitaxel alone (group A) and 16 with paclitaxel and adriamycin (group B). Pattern visual evoked potentials (VEPs), and transient, 30 Hz flicker (FLK) and oscillatory potential (OP) white flash electroretinograms (ERGs), were recorded before treatment, after the third and sixth therapeutic cycle, and at the end of the programmed regimen. Pretreatment: Abnormal VEP and OP and FLK changes occurred more than 75% of patients; transient ERGs were normal in more than 90%. Serial recordings: VEPs remained unchanged in both goups. In group A, ERG b-wave latency significantly increased (ANOVA P
AB - As paclitaxel may induce positive spontaneous visual symptoms or persistent visual loss, we carried out this electrophysiological study in an attempt to clarify the underlying pathophysiological mechanisms of visual pathway involvement. The study involved 30 breast cancer patients: 14 were treated with paclitaxel alone (group A) and 16 with paclitaxel and adriamycin (group B). Pattern visual evoked potentials (VEPs), and transient, 30 Hz flicker (FLK) and oscillatory potential (OP) white flash electroretinograms (ERGs), were recorded before treatment, after the third and sixth therapeutic cycle, and at the end of the programmed regimen. Pretreatment: Abnormal VEP and OP and FLK changes occurred more than 75% of patients; transient ERGs were normal in more than 90%. Serial recordings: VEPs remained unchanged in both goups. In group A, ERG b-wave latency significantly increased (ANOVA P
KW - Chemotherapy
KW - Electroretinogram
KW - Ocular toxicity
KW - Paclitaxel
KW - Tamoxifen
KW - Visual evoked potentials
UR - http://www.scopus.com/inward/record.url?scp=33745056075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745056075&partnerID=8YFLogxK
U2 - 10.1007/s11060-005-9008-x
DO - 10.1007/s11060-005-9008-x
M3 - Article
C2 - 16132528
AN - SCOPUS:33745056075
VL - 77
SP - 79
EP - 87
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
SN - 0167-594X
IS - 1
ER -